GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (FRA:XP0) » Definitions » EV-to-EBIT

Xenon Pharmaceuticals (FRA:XP0) EV-to-EBIT : -10.35 (As of Oct. 31, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Xenon Pharmaceuticals's Enterprise Value is €2,275.63 Mil. Xenon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-219.93 Mil. Therefore, Xenon Pharmaceuticals's EV-to-EBIT for today is -10.35.

The historical rank and industry rank for Xenon Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

FRA:XP0' s EV-to-EBIT Range Over the Past 10 Years
Min: -32.58   Med: -7.96   Max: 89.8
Current: -10.37

During the past 13 years, the highest EV-to-EBIT of Xenon Pharmaceuticals was 89.80. The lowest was -32.58. And the median was -7.96.

FRA:XP0's EV-to-EBIT is ranked worse than
100% of 419 companies
in the Biotechnology industry
Industry Median: 10.01 vs FRA:XP0: -10.37

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Xenon Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2024 was €1,987.38 Mil. Xenon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-219.93 Mil. Xenon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -11.07%.


Xenon Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Xenon Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals EV-to-EBIT Chart

Xenon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.26 -13.02 -13.64 -14.61 -13.29

Xenon Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.34 -8.37 -13.29 -11.42 -9.43

Competitive Comparison of Xenon Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Xenon Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's EV-to-EBIT falls into.



Xenon Pharmaceuticals EV-to-EBIT Calculation

Xenon Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2275.625/-219.93
=-10.35

Xenon Pharmaceuticals's current Enterprise Value is €2,275.63 Mil.
Xenon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-219.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xenon Pharmaceuticals  (FRA:XP0) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Xenon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-219.93/1987.3775
=-11.07 %

Xenon Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2024 was €1,987.38 Mil.
Xenon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-219.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xenon Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Xenon Pharmaceuticals Headlines

No Headlines